Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Organoid COMMONS appoints its Governing Board and Alliance Director. Member applications are open through April 30, 2026.
-
Asimov partners with Score Pharma to develop biosuperior antibody therapeutics with enhanced ADCC activity using Asimov's CHO Edge platform.
-
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.
-
Solve GNE highlights new research, expanded funding efforts, and progress toward a Phase I clinical trial for GNE myopathy.
-
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
-
BEIJING, March 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced...
-
Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
-
Introducing Rozum: an AI reasoning engine built for high-stakes decisions - and the highest-scoring system on Humanity's Last Exam. Now in early access.
-
Claret Capital Partners, Europe's largest independent growth debt fund manager has made an investment, through its Fund IV, of up to EUR 28m
-
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.